Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11989367 | 0.92 | MAPT (0.35) | ACACBACACATSHRMAPTALDH1A1 | |
| SCHEMBL812254 | 0.90 | BACE1 (0.34) | ACACBACACATSHRBACE1MAPT | |
| SCHEMBL27374303 | 0.89 | TSHR (0.33) | TSHRMAPT | |
| SCHEMBL30737090 | 0.86 | TSHR (0.36) | TSHRMAPT | |
| SCHEMBL30737150 | 0.85 | TSHR (0.31) | TSHR | |
| SCHEMBL27378208 | 0.85 | TSHR (0.31) | TSHR | |
| SCHEMBL811977 | 0.84 | ACACB (0.44) | ACACBACACABACE1 | |
| SCHEMBL11989368 | 0.83 | ALDH1A1 (0.40) | ACACBACACATSHRMAPTALDH1A1 | |
| SCHEMBL13039853 | 0.83 | TSHR (0.32) | TSHR | |
| SCHEMBL11986867 | 0.83 | TSHR (0.39) | TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962599-B1 | INSECTICIDE COMPOUNDS WITH IMPROVED EFFECT | BAYER IP GMBH (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-8247351-B2 | Insecticidal compositions having improved effect | BAYER CROPSCIENCE AG (DE) | 2012-08-21 | — | — | US | disclosed |
| US-8247351-B2 | Insecticidal compositions having improved effect | BAYER CROPSCIENCE AG (DE) | 2012-08-21 | — | — | US | disclosed |
| US-20110294783-A1 | Insecticidal Compositions Having Improved Effect | BAYER CROPSCIENCE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294783-A1 | Insecticidal Compositions Having Improved Effect | BAYER CROPSCIENCE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20090209513-A1 | Insecticidal Compositions Having Improved Effect | BAYER CROPSCIENCE AG (DE) | 2009-08-20 | — | — | US | disclosed |
| US-20090209513-A1 | Insecticidal Compositions Having Improved Effect | BAYER CROPSCIENCE AG (DE) | 2009-08-20 | — | — | US | disclosed |
| WO-2007068428-A2 | INSECTICIDAL COMPOSITIONS CONTAINING PHENYL-SUBSTITUTED CYCLIC KETOENOLS | BAYER CROPSCIENCE AG (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294783-A1 | Insecticidal Compositions Having Improved Effect | FASN, CYP51A1, PIKFYVE | ACACB 58/4885ACACA 41/4885TSHR 4115/4885 |
| US-20090209513-A1 | Insecticidal Compositions Having Improved Effect | PTEN, PIK3CG, PIK3CD | ACACB 632/4885ACACA 382/4885TSHR 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.